Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database

Carfilzomib is an active and commonly used treatment in patients with multiple myeloma (MM). Using the Canadian Myeloma Research Group Database, we performed a retrospective observational study of patients treated with carfilzomib for relapse of MM in a real‐world setting in Canada between years 200...

Descripción completa

Detalles Bibliográficos
Autores principales: McCurdy, Arleigh, Louzada, Martha, Venner, Christopher P., Visram, Alissa, Masih‐Khan, Esther, Kardjadj, Moustafa, Jimenez‐Zepeda, Victor H., LeBlanc, Richard, Sebag, Michael, Song, Kevin, White, Darrell, Mian, Hira, Stakiw, Julie, Reiman, Anthony, Aslam, Muhammad, Kotb, Rami, Gul, Engin, Reece, Donna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematologic Malignancy ‐ Plasma Cell
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713064/
https://www.ncbi.nlm.nih.gov/pubmed/36467802
http://dx.doi.org/10.1002/jha2.559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713064/
https://www.ncbi.nlm.nih.gov/pubmed/36467802
http://dx.doi.org/10.1002/jha2.559

Ejemplares similares